Posted inBiotechnology
Posted inBiotechnology
UCB’s orchestra hits dud note: Novartis-partnered Parkinson’s asset fails phase 2
UCB’s Novartis-partnered investigational small molecule has failed to improve symptoms of Parkinson’s disease in a phase 2a trial. The oral…




















